PRTG Jul 2024 2.500 call
| Previous close | 0.0500 |
| Open | 0.4100 |
| Bid | 0.0000 |
| Ask | 0.3000 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.0500 - 0.4100 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswirePortage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
-Adenosine clinical development pausedWESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway. After a review of the Company’s future funding needs for clinical development of its adenosine an
- GlobeNewswire
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Company generated approximately $2.8M of non-dilutive funding to extend cash runwayWESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it has completed selling its equity holding in Intensity Therapeutics (NASDAQ: INTS). Portage was an early INTS investor and during the past few months, Portage has been able to monet
- GlobeNewswire
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
Company focused on adenosine platform clinical developmentWESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023. “The Company is focused on advancing its ADPORT-201 Phase 1a/1b clinical trial of PORT-6 (adenosine 2A inhibitor) and P
